The figures also suggest that the NI economy may have been performing better than the UK average. However those comparisons need to be treated with caution as the NI and UK figures are not fully ...

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

But despite reports that he could be on his way out of the west Midlands, sources have revealed that Duran won't be leaving in the winter window - with a huge price tag set on his talents.

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Unai Emery has put a stop to Jhon Duran's potential exit this month, expressing his desire for both him and Ollie Watkins to remain at Villa Park for the next decade. The Aston Villa manager has ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

Aston Villa have rejected a bid in the region of £40m from West Ham for striker Jhon Duran. (Talksport, external) Celtic are one of several clubs interested in signing Villa forward Louie Barry ...

In come Emi Martinez, Lucas Digne, Jacob Ramsey and Amadou Onana, while Jhon Duran returns to the bench after serving a three-match suspension. From back to front, Martinez starts in goal behind a ...

It’s also how much stood between the Red Sox and Jarren Duran at last week’s deadline to avoid going to arbitration. Duran filed at $4 million, his club offered $3.5 million. Come on.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.